NeuroPace (NPCE) Tops Q1 EPS by 2c, provides guidance

NeuroPace (NASDAQ: NPCE) reported Q1 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $21.65 million.

GUIDANCE:

NeuroPace sees FY2026 revenue of $99-101 million, versus the consensus of $98.884 million.
Reiterate full year non-GAAP gross margin between 81.5% and 82.5%
Reiterate full year non-GAAP operating expenses to be between $90 million and $92 million, excluding approximately $10 million in stock-based compensation, a non-cash expense
Increase Adjusted EBITDA to be between ($8.5) and ($9.5) million compared to previous guidance between ($9.0) million to ($10.0) million

For earnings history and earnings-related data on NeuroPace (NPCE) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c